ADAP Crisis Task Force Reaches Agreements With Three Pharmaceutical Companies to Assist Struggling ADAPs; Additional Federal and State Funding Required

Washington, D.C. -- With 1,056 people on waiting lists and many other access restrictions in place for individuals to receive consistent access to their HIV-related medications through AIDS Drug Assistance Programs (ADAPs), the ADAP Crisis Task Force (ACTF) announced that it has reached agreements with Abbott Laboratories, Merck and Co., Inc. and Tibotec Therapeutics to bring fiscal relief to the nation's state-administered ADAPs. The agreements are enhancements of long-term, existing partnerships and will help achieve savings through a mix of program adjustments including increased discounts and rebates for HIV antiretroviral treatments, price freezes on some medications as well as improved access to pharmaceutical Patient Assistance Programs (PAPs) for clients on ADAP waiting lists.